SECURITIES | 2026-10-18

Item 303 of Regulation S-K and the Duty to Disclose Known Trends: How MD&A Disclosure Obligations Work, and Why Macquarie v. Moab Limits Private 10b-5 Claims Built on Pure Omissions

A public company’s Management’s Discussion and Analysis must disclose known trends and uncertainties reasonably likely to affect its results — that is Item 303 of Regulation S-K. But a 2024 Supreme Court decision drew a sharp line between what Item 303 requires and when a private securities-fraud claim can be built on a failure to make that disclosure.

A public company does not satisfy the securities laws merely by reporting accurate numbers; it must also explain, in its Management’s Discussion and Analysis (MD&A), the known trends and uncertainties that are reasonably likely to affect those numbers going forward. That forward-looking narrative du

Investors rely on a public company’s periodic reports not only for the hard financial statements but for management’s explanation of what those numbers mean and where the business is heading. The securities laws capture that need in a specific disclosure requirement — Item 303 of Regulation S-K — which governs the Management’s Discussion and Analysis section of annual and quarterly reports. Item 303 is where a company must surface the known trends and uncertainties that could materially affect its future results. For years, plaintiffs tried to convert a company’s failure to make an Item 303 disclosure into a private securities-fraud claim. In 2024, the Supreme Court drew a firm line around that theory. Understanding both the affirmative disclosure duty and the limits on private enforcement is essential for issuers building their reports and for investors evaluating their remedies.

What MD&A Is and Why It Exists

The Management’s Discussion and Analysis section of a company’s Form 10-K (annual) and Form 10-Q (quarterly) reports is management’s narrative explanation of the company’s financial condition and results of operations. Its purpose is to let investors see the business through the eyes of management — to understand not just what the numbers are, but why they moved, what drove them, and what is reasonably likely to affect them in the future. MD&A bridges the gap between static financial statements and the forward-looking judgment investors need. Because it is narrative and forward-looking, MD&A is also where disclosure questions become hardest: management must decide what trends and uncertainties are material enough, and likely enough, to require disclosure, and must do so without the benefit of hindsight. Item 303 is the rule that structures those decisions.

Item 303 and the Known-Trends Requirement

Item 303 of Regulation S-K requires a company to disclose, among other things, any known trends, events, or uncertainties that have had or are reasonably likely to have a material favorable or unfavorable effect on net sales, revenues, income, liquidity, or capital resources. The requirement is forward-looking: it reaches not only what has already happened but what management knows and reasonably expects. The SEC has long explained the standard through a two-part inquiry: first, is the known trend or uncertainty likely to come to fruition? If management cannot make that determination, it must assume it will. Second, if it does come to fruition, is a material effect on the company’s financial condition or results reasonably likely? If so, disclosure is required. This framework pushes companies to disclose material, reasonably likely future impacts rather than wait until they materialize, and it is the analytical core of MD&A preparation.

Item 303 Is a Disclosure Rule, Not a Private Cause of Action

A crucial point, underscored by the Supreme Court, is that Item 303 is a disclosure regulation administered by the SEC — it does not itself create a private right of action. A company that violates Item 303 can face SEC enforcement, but an investor cannot sue directly “under Item 303.” Investors who want a private remedy must fit their claim within a provision that does provide one — most commonly Section 10(b) of the Securities Exchange Act and SEC Rule 10b-5. The question that divided the lower courts for years, and that the Supreme Court finally resolved in 2024, was whether a company’s failure to make a required Item 303 disclosure — standing alone — could be the basis of a private Rule 10b-5 claim. The answer turns on the precise language of Rule 10b-5(b) and the difference between a pure omission and a misleading half-truth.

Rule 10b-5(b): Half-Truths Versus Pure Omissions

Rule 10b-5(b) makes it unlawful to make any untrue statement of a material fact or to omit to state a material fact necessary in order to make the statements made … not misleading. The structure of that language matters. The omission clause is tethered to statements made: it prohibits leaving out a fact that is needed to keep something the company actually said from being misleading. That is the classic half-truth — a literally true statement rendered misleading by what it leaves out. What Rule 10b-5(b) does not do, by its terms, is impose a freestanding duty to disclose every material fact; it does not make pure silence actionable where the company has said nothing on the subject at all. This textual distinction — between an omission that makes an actual statement misleading and a pure omission with no related statement — is the fulcrum on which Macquarie turned.

Macquarie Infrastructure Corp. v. Moab Partners (2024)

In Macquarie Infrastructure Corp. v. Moab Partners, L.P. (2024) 601 U.S. 257, the Supreme Court held that a pure omission of information that Item 303 requires cannot support a private claim under Rule 10b-5(b). The plaintiffs alleged that the company failed to disclose, as Item 303 required, a known trend relating to the declining demand for a high-sulfur fuel product affected by a new international regulation. The Court reasoned that Rule 10b-5(b)’s omission clause requires identifying affirmative statements that the omission rendered misleading; a failure to disclose under Item 303, by itself, is a pure omission, not a half-truth, and therefore is not actionable under Rule 10b-5(b) absent a misleading statement that the omitted information was necessary to correct. The Court was explicit that this does not leave Item 303 unenforceable — the SEC can enforce it — and that its holding does not disturb a company’s separate obligation not to make misleading half-truths. The decision resolved a circuit split (the Second Circuit had allowed such claims; others had not) in favor of the narrower reading.

What Macquarie Did — and Did Not — Change

Macquarie is important, but its scope should be understood precisely. It did not weaken Item 303 as a disclosure obligation: companies must still comply, and the SEC can still enforce. It did not immunize companies that make misleading statements: if a company speaks on a subject and omits a fact needed to keep what it said from being misleading, that half-truth remains actionable under Rule 10b-5(b), and Item 303’s requirements can inform what a reasonable investor would expect the company to have disclosed in that context. What Macquarie did change is that plaintiffs can no longer build a private Rule 10b-5(b) claim on the bare fact that a company failed to make an Item 303 disclosure, without tying the omission to a misleading affirmative statement. For plaintiffs, that means pleading a statement the omission rendered misleading; for defendants, it is a powerful tool to dismiss claims premised on pure Item 303 silence.

Materiality Still Governs

Whether the claim is framed as a misstatement or an actionable half-truth, materiality remains an essential element, governed by the familiar standard of Basic Inc. v. Levinson (1988) 485 U.S. 224: a fact is material if there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision, assessed in the total mix of available information. Item 303’s “reasonably likely” trend standard and Rule 10b-5’s materiality standard are related but distinct inquiries; a trend can be disclosable under Item 303 and also material under Basic, but the Item 303 analysis asks about likelihood and expected effect, while materiality asks about importance to a reasonable investor. After Macquarie, a plaintiff must show both that there was a misleading statement (or half-truth) and that the omitted information was material — materiality alone does not convert pure silence into liability.

Scienter and the Other 10b-5 Elements

A private Rule 10b-5 claim requires more than a material misstatement or misleading half-truth. The plaintiff must also plead and prove scienter — a mental state embracing intent to deceive or, in most circuits, recklessness — and under the Private Securities Litigation Reform Act must plead facts giving rise to a strong inference of scienter, the standard the Supreme Court set in Tellabs, Inc. v. Makor Issues & Rights, Ltd. (2007) 551 U.S. 308. The plaintiff must also establish reliance (often through the fraud-on-the-market presumption), economic loss, and loss causation. Macquarie addressed only the threshold question of whether a pure Item 303 omission is actionable conduct under Rule 10b-5(b); even where a plaintiff can point to a misleading half-truth, the claim must still clear scienter, reliance, and loss-causation hurdles. For issuers, this layered structure means that disciplined, accurate disclosure is the first and best defense, well before the harder elements come into play.

What Issuers Should Take From Item 303 and Macquarie

For public companies, the practical lessons are clear. First, comply with Item 303 on its own terms: identify known trends and uncertainties, apply the two-part likelihood-and-materiality analysis, and disclose what the rule requires — because the SEC can and does enforce it regardless of the private-litigation landscape. Second, mind the half-truth risk: Macquarie protects pure silence, but the moment a company speaks on a subject, it takes on a duty not to mislead, and an incomplete or selectively favorable statement can be actionable. Third, maintain strong disclosure controls so that the people who know about emerging trends feed that information into the drafting process. And fourth, document the disclosure judgments made — the trends considered and the reasons for the disclosure decisions — so the company can defend its process if challenged. Macquarie narrows one avenue of private liability, but it does not reduce the importance of getting MD&A right.

What Investors Should Take From Macquarie

For investors and their counsel, Macquarie changes how a disclosure claim must be framed. A complaint can no longer rest on the assertion that the company “should have disclosed a trend under Item 303” and stop there. Instead, the plaintiff must identify an affirmative statement the company made — in MD&A, a press release, an earnings call, or elsewhere — that the omission rendered misleading, and must connect the omitted trend to that statement. This is often achievable, because companies that fail to disclose a material adverse trend frequently also make optimistic or incomplete statements about the same subject; the omitted trend is what made those statements misleading. The task is to plead that linkage with particularity, together with scienter, reliance, and loss causation. Experienced securities counsel can assess whether a given set of facts supports an actionable half-truth claim after Macquarie or falls on the pure-omission side of the line the Supreme Court drew.

Item 303 in the Broader Disclosure Framework

Item 303 does not operate in isolation; it is one piece of a layered disclosure regime that public companies must navigate together. Regulation S-K also requires, among other things, a discussion of material risk factors and a narrative business description, and the federal securities laws impose their own antifraud overlay under Section 10(b) and Rule 10b-5. A known trend that must be surfaced in MD&A under Item 303 may also need to be reflected in the company’s risk-factor disclosure and in its public statements generally, and the same underlying facts can implicate several requirements at once. After Macquarie, the critical analytic step is to distinguish between a pure disclosure obligation (enforceable by the SEC but not, standing alone, by private plaintiffs) and an affirmative statement that triggers a duty not to mislead (enforceable privately under Rule 10b-5(b) as a half-truth). Companies that coordinate their MD&A, risk factors, and public communications — so that what they say in one place is consistent with what they disclose in another — reduce both the risk of an SEC enforcement action for an Item 303 violation and the risk that an optimistic or selective statement elsewhere becomes an actionable half-truth. Treating disclosure as an integrated whole, rather than a set of disconnected checklist items, is the most reliable way to manage the combined exposure that Item 303 and Rule 10b-5 create.

Related Guides

• California Securities & Corporate Governance Lawyers
• Rule 10b-5 Securities Fraud: The Elements of a Private Claim for California Investors
• Rule 14e-3 and Insider Trading in Tender Offers

Frequently Asked Questions

What is Item 303 of Regulation S-K?

Item 303 is the SEC disclosure rule that governs Management’s Discussion and Analysis (MD&A) in annual and quarterly reports. Among other things, it requires a company to disclose known trends, events, or uncertainties that are reasonably likely to have a material effect on its net sales, revenues, income, liquidity, or capital resources — a forward-looking narrative duty that lets investors see the business through management’s eyes.

What is the Item 303 known-trends test?

The SEC frames it as a two-part inquiry: first, is the known trend or uncertainty likely to come to fruition (if management can’t tell, it must assume it will); second, if it does, is a material effect on financial condition or results reasonably likely? If so, disclosure is required. The focus is on reasonably likely future impacts, not only events that have already occurred.

Can an investor sue directly under Item 303?

No. Item 303 is a disclosure regulation enforced by the SEC; it does not create a private right of action. An investor seeking a private remedy must fit the claim within a provision that provides one, most often Section 10(b) and Rule 10b-5.

What did Macquarie v. Moab decide?

In Macquarie Infrastructure Corp. v. Moab Partners (2024) 601 U.S. 257, the Supreme Court held that a pure omission of information required by Item 303 cannot, by itself, support a private claim under Rule 10b-5(b). That rule’s omission clause reaches half-truths — omissions that make statements actually made misleading — not freestanding silence. The SEC can still enforce Item 303.

What is the difference between a half-truth and a pure omission?

A half-truth is a literally true statement rendered misleading by a fact left out; it is actionable under Rule 10b-5(b) because the omission is tied to a statement actually made. A pure omission is silence on a subject the company never addressed. After Macquarie, pure omissions — including a bare failure to make an Item 303 disclosure — are not actionable under Rule 10b-5(b) without a connected misleading statement.

Does Macquarie make MD&A disclosure less important?

No. Companies must still comply with Item 303, and the SEC can enforce it. Macquarie also leaves half-truth liability intact: once a company speaks on a subject, it must not mislead by omission. The decision narrows one private-litigation theory; it does not reduce the importance of accurate, complete MD&A. Call Trembach Law Firm at (818) 514-7680 for disclosure counsel.

What else must a private Rule 10b-5 claim prove?

Beyond an actionable misstatement or half-truth, a plaintiff must plead and prove scienter (with a strong inference under Tellabs and the PSLRA), reliance (often via fraud-on-the-market), economic loss, and loss causation, and the misstatement must be material under Basic v. Levinson. Macquarie addressed only whether a pure Item 303 omission is actionable conduct in the first place.

How can my company reduce Item 303 litigation risk?

Comply with Item 303 on its terms, apply the likelihood-and-materiality analysis to known trends, avoid optimistic or selective statements that an omission could render misleading, maintain strong disclosure controls, and document the disclosure judgments you make. These steps address both SEC enforcement and private half-truth exposure. Call Trembach Law Firm at (818) 514-7680.

Talk to a California Securities Lawyer About Disclosure Obligations

Item 303 requires public companies to disclose known trends and uncertainties in MD&A, and Macquarie v. Moab drew a precise line between actionable half-truths and non-actionable pure omissions under Rule 10b-5. Trembach Law Firm, led by Anatolii Trembach (LL.M.; admitted in California), advises issuers and investors on MD&A disclosure, the post-Macquarie litigation landscape, and the disclosure controls that reduce risk. Call (818) 514-7680 for a confidential consultation.

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301